BRAF Alteration in Central and Peripheral Nervous System Tumors
BRAF (alternately referred to as v-raf murine sarcoma viral oncogene homolog B1) is a proto-oncogene involved in the mitogen-activated protein kinase (MAPK) pathway. BRAF alterations are most commonly missense mutations or aberrant fusions. These mutations are observed in numerous primary central ne...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-09-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fonc.2020.574974/full |
id |
doaj-68521594071c41a8a7450daba24c6848 |
---|---|
record_format |
Article |
spelling |
doaj-68521594071c41a8a7450daba24c68482020-11-25T02:54:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-09-011010.3389/fonc.2020.574974574974BRAF Alteration in Central and Peripheral Nervous System TumorsKomal Srinivasa0Kevin A. Cross1Sonika Dahiya2Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, United StatesDepartment of Neurosurgery, Washington University School of Medicine, St. Louis, MO, United StatesDepartment of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO, United StatesBRAF (alternately referred to as v-raf murine sarcoma viral oncogene homolog B1) is a proto-oncogene involved in the mitogen-activated protein kinase (MAPK) pathway. BRAF alterations are most commonly missense mutations or aberrant fusions. These mutations are observed in numerous primary central nervous system tumors as well as metastases. This review discusses the prevalence of BRAF alteration within select notable CNS tumors, and their prognostic associations. Included are some novel entities such as diffuse leptomeningeal glioneuronal tumor (DLGNT), polymorphous low grade neuroepithelial tumor of the young (PLNTY), and multinodular and vacuolating neuronal tumor (MVNT). Knowledge of this gene’s integrity in CNS and PNS tumors can have profound diagnostic and therapeutic implications. Also reviewed are the current state of targeted therapy against aberrant BRAF as it pertains mostly to the CNS and to a lesser extent in PNS, and certain diagnostic aspects.https://www.frontiersin.org/article/10.3389/fonc.2020.574974/fullBRAFCNSPNStumordiagnosisprognosis |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Komal Srinivasa Kevin A. Cross Sonika Dahiya |
spellingShingle |
Komal Srinivasa Kevin A. Cross Sonika Dahiya BRAF Alteration in Central and Peripheral Nervous System Tumors Frontiers in Oncology BRAF CNS PNS tumor diagnosis prognosis |
author_facet |
Komal Srinivasa Kevin A. Cross Sonika Dahiya |
author_sort |
Komal Srinivasa |
title |
BRAF Alteration in Central and Peripheral Nervous System Tumors |
title_short |
BRAF Alteration in Central and Peripheral Nervous System Tumors |
title_full |
BRAF Alteration in Central and Peripheral Nervous System Tumors |
title_fullStr |
BRAF Alteration in Central and Peripheral Nervous System Tumors |
title_full_unstemmed |
BRAF Alteration in Central and Peripheral Nervous System Tumors |
title_sort |
braf alteration in central and peripheral nervous system tumors |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Oncology |
issn |
2234-943X |
publishDate |
2020-09-01 |
description |
BRAF (alternately referred to as v-raf murine sarcoma viral oncogene homolog B1) is a proto-oncogene involved in the mitogen-activated protein kinase (MAPK) pathway. BRAF alterations are most commonly missense mutations or aberrant fusions. These mutations are observed in numerous primary central nervous system tumors as well as metastases. This review discusses the prevalence of BRAF alteration within select notable CNS tumors, and their prognostic associations. Included are some novel entities such as diffuse leptomeningeal glioneuronal tumor (DLGNT), polymorphous low grade neuroepithelial tumor of the young (PLNTY), and multinodular and vacuolating neuronal tumor (MVNT). Knowledge of this gene’s integrity in CNS and PNS tumors can have profound diagnostic and therapeutic implications. Also reviewed are the current state of targeted therapy against aberrant BRAF as it pertains mostly to the CNS and to a lesser extent in PNS, and certain diagnostic aspects. |
topic |
BRAF CNS PNS tumor diagnosis prognosis |
url |
https://www.frontiersin.org/article/10.3389/fonc.2020.574974/full |
work_keys_str_mv |
AT komalsrinivasa brafalterationincentralandperipheralnervoussystemtumors AT kevinacross brafalterationincentralandperipheralnervoussystemtumors AT sonikadahiya brafalterationincentralandperipheralnervoussystemtumors |
_version_ |
1724720620357287936 |